Abstract Library

#3935 Single-cell sequencing reveals the heterogeneity of pancreatic neuroendocrine tumors under the pattern of genomic instability and histological grading

Introduction: Non-functional pancreatic neuroendocrine tumor (NF-Pan-NET) is a kind of highly heterogeneous tumors. Histological grading is the key factors affecting the prognosis of patients and instructive in guiding treatment and assessing recurrence in NF-Pan-NET. 90% of NF-Pan-NET are grade G1 or G2, leading to an unpredictable clinical course that varies from indolent to highly malignant. Approximately one-third of patients without CNV alteration and the prognosis of these patients are better than that of patients with CNV alteration. Therefore, probing the heterogeneity of tumors based on histological grading and CNV variation is crucial.

Conference:

Presenting Author: Ye Z

Authors: Ye Z, Zhou C, Xu X, Chen J, Yu X,

Keywords: Pancreatic neuroendocrine tumor, single-cell sequencing, genomic instability, histological grading,

#3852 Novel insights to study the potential of the somatostatin system in NETs and NECs

Introduction: Neuroendocrine tumors (NETs) and carcinomas (NECs) are a heterogeneous group of cancers with increasing incidence worldwide. Surgery is the only curative choice, whereas an effective pharmacological approach for disseminated disease is still lacking. Somatostatin (SS) receptors (SSTs) provide a suitable pharmacological target to treat NETs with SS analogues (SSAs). However, a large proportion of NETs and, particularly most NECs, are unresponsive or resistant to SSAs. The underlying causes remain poorly understood and alternative strategies are needed. Recently, cortistatin (CST), a neuropeptide analogue of SS with comparable affinity to SSTs, emerged as an anti-inflammatory player, with potential antitumoral features.

Conference:

Presenting Author: Mangili F

Authors: Mangili F, Moreno Montilla M, García Vioque V, Blázquez-Encinas R, Mantovani G,

Keywords: PanNET, PanNEC, Somatostatin receptor (SST), cortistatin, Somatostatin,

#3468 Novel morphological tools in predicting pancreatic neuroendocrine tumors (Pan-Net) clinical outcome

Introduction: Pancreatic Neuroendocrine Tumor (Pan-NET) clinical outcome shows a high variability among patients within the same World Health Organization (WHO) category. To date, there is a lack of markers to predict recurrence after resection, which makes it difficult to identify patients with higher risk of progression.

Conference:

Presenting Author:

Authors: Lagano V, Sabella G, Cattaneo L, Grillo F, Mangogna A,

Keywords: Pancreas, parenchymal infiltration, tumor deposits,

#3122 Plasma protein biomarkers for the detection of pancreatic neuroendocrine tumors (Pan-NET) and differentiation from small intestinal (SI) NET

Introduction: There is an unmet need for novel biomarkers to diagnose and monitor patients with Pan-NET and SI-NET.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Thiis-Evensen E

Authors: Thiis-Evensen E, Kjellman M, Knigge U, Gronbaek H, Schalin-Jäntti C,

Keywords: detection, Pan-NET, SI-NET, biomarker, plasma protein, machine learning,

#3047 Functional Consequence of β-Arrestin 1 Gene Knock-Out in Pancreatic Neuroendocrine Tumor Cell Line BON-1

Introduction: An important limiting factor influencing treatment efficacy of neuroendocrine tumors (NETs) with somatostatin analogs (SSA) is the availability of somatostatin receptors (SSTR) on NETs. While downregulation or altered pattern of SSTR expression are important considerations, receptor internalization/desensitization by β-arrestins may be a crucial contributing factor. Interestingly, our previous study showed a preferential higher expression of β-arrestin 1 (ARRB1), in gastroenteropancreatic NETS (GEP-NETs) compared to pituitary adenomas.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Iyer A

Authors: Iyer A, Vriens J, Dogan-Oruç F, van Koetsveld P, Hofland L,

Keywords: β-arrestin 1, CRISPR-Cas9, BON-1, knock-out, SSTR, SSA, Pan-NET,